A specialist healthcare company with offices in Europe, North America, and Australia is actively looking to in-license and acquire innovative therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 million and more for later-stage acquisitions. The firm is most interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.
The firm is interested in therapeutic assets and medical devices, particularly interventional medicine products that can be used to advance the treatment of cancer, cardiovascular, and pulmonary diseases. The firm is open to therapeutics within these areas as well as other indications, pending they are intended to be hospital products. The firm is primarily interested in small molecule therapeutics and is focused on late-stage/marketed products at the current time.
For medical devices, the firm is looking for companies that have 510K approval in oncology, vascular and pulmonary fields. The firm’s current device products include interventional oncology products used to treat patients with liver tumors, interventional vascular products used to treat patients with severe blood clots, and investigational devices for the treatment of severe emphysema.
The firm is interested in working with founding management teams prior to investment and is open to in-licensing from public and private clients.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment